Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Reovirus Target Population

<< Previous

Bullboard Posts

Next >>

Comment by Journeytcon Dec 18, 2023 6:33pm

150 Views

Post# 35790813

RE:RE:Reovirus Target Population

Due to sensitivity I will refrain from remarking further on the vax. What ever happens good or bad will become clear in time. It is related to ONC's business and growth potential for sure. I'm crickets here forward.

<< Previous

Bullboard Posts

Next >>

Enbridge finalizes acquisition of three growing gas utilities